Group 1 - The core viewpoint of the article is that HaiXin Co., Ltd. is progressing with the APDC Phase III clinical trial project through its subsidiary HaiXin Bio [2] Group 2 - HaiXin Co., Ltd. responded to investor inquiries on an interactive platform regarding the status of its clinical trial [2] - The APDC Phase III clinical trial is still ongoing, indicating continued development efforts in the company's biopharmaceutical initiatives [2]

Group 1 - The core point of the article is that HaiXin Co., Ltd. (600851.SH) has confirmed that its subsidiary, HaiXin Bio, is continuing to advance the Phase III clinical trial project for APDC [1] Group 2 - The company is actively engaging with investors through its interactive platform to provide updates on its clinical trial progress [1]

Core Viewpoint - The company reported a slight decline in revenue for Q1 2025, while net profit showed a modest increase, indicating mixed performance in the current financial period [1]. Financial Performance - For Q1 2025, the company's operating revenue was 202 million yuan, a year-on-year decrease of 3.02% - The net profit attributable to shareholders was 33.02 million yuan, reflecting a year-on-year increase of 2.58% [1] - The sales net profit margin stood at 18.45%, and the return on equity was 0.77% as of Q1 2025 [2]. Industry Policy and Environment - The launch of China's drug price registration system in December 2025 is expected to enhance price transparency in the pharmaceutical sector, which may have long-term implications for chemical pharmaceutical companies like Hai Xin [3]. Capital Movement - As of the week ending December 19, 2025, the company experienced a net outflow of main funds amounting to 7.3273 million yuan, with the stock price closing at 7.13 yuan, reflecting a weekly increase of 3.48% [4].

Group 1 - The company emphasizes the importance of coordinating operational quality with market value management, adhering to a sustainable development philosophy [2] - The company is committed to improving internal management mechanisms and enhancing operational efficiency to achieve high-quality development [2] - The company aims to create better returns for investors through its management efforts [2]

| | | 上海海欣集团股份有限公司 关于独立董事离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海海欣集团股份有限公司（以下简称公司）董事会于近日收到独立董事何胜友 先生的书面辞职报告。何胜友先生因连续任职已满六年，申请辞去公司独立董事职务， 同时辞去所担任的董事会专门委员会相关职务。辞职后，何胜友先生将不再担任公司 任何职务。因其辞职将导致公司独立董事人数少于董事会成员的三分之一且董事会相 关专门委员会独立董事所占比例不符合相关规定，在公司股东会选举产生新任独立董 事之前，何胜友先生仍将继续履行其作为独立董事及董事会专门委员会委员的相关职 责。公司将按照有关规定，尽快完成补选。 2026 年 1 月 21 日 2 一、 独立董事离任的基本情况 1 二、 离任对公司的影响 根据《公司法》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》 及《公司章程》等有关规定，何胜友先生的辞职将导致公司独立董事人数少于董事会 成员的三分之一且董事会相关专门委员会独立董事所占比例不符合相关规定，在公司 ...

Core Viewpoint - The recent approval of the "Vitamin B6 Injection" by Jiangxi Gannan Haixin Pharmaceutical Co., Ltd. is expected to enhance market competitiveness, although it will not significantly impact the company's current operating performance [1][2]. Company Announcement Summary - Haixin Co., Ltd. reported a stock price of 7.01 yuan as of December 26, 2025, down 1.68% from the previous week [1]. - The stock reached a high of 7.24 yuan and a low of 7.00 yuan during the week [1]. - The company's current total market capitalization is 8.461 billion yuan, ranking 64th out of 151 in the chemical pharmaceutical sector and 2213th out of 5178 in the A-share market [1]. - The "Vitamin B6 Injection" has been approved by the National Medical Products Administration and is classified as a Class A drug under the national medical insurance and essential drug list, with an estimated sales volume of approximately 304 million yuan in public medical institutions for 2024 [1][2]. - The successful completion of the consistency evaluation for the generic drug is expected to improve product competitiveness [2].

Core Viewpoint - Shanghai Haixin Group's subsidiary, Jiangxi Gannan Haixin Pharmaceutical Co., Ltd., has received approval for its Vitamin B6 injection to pass the consistency evaluation of quality and efficacy for generic drugs, enhancing its market competitiveness and experience for future drug development [1][6]. Group 1: Drug Information - The drug is named Vitamin B6 Injection, in the form of an injection with a specification of 1ml:0.1g, classified as a chemical drug [1]. - The approval number for the drug is H20258295, and it has been granted a 12-month validity period [1]. - The drug is indicated for the prevention and treatment of Vitamin B6 deficiency, as well as for various conditions such as pregnancy-related issues and certain metabolic disorders [2][3][4]. Group 2: Market Situation - Vitamin B6 is a water-soluble vitamin that cannot be synthesized by the human body and must be obtained through diet or intravenous injection [7]. - The injection is classified as a Category A drug under national medical insurance and is included in the national essential drug list, indicating its widespread application in disease prevention and treatment [7]. - According to the Minet database, the sales revenue of Vitamin B6 injection in public medical institutions in China is projected to be approximately RMB 304 million in 2024 [7]. Group 3: Impact on the Company - The approval of Vitamin B6 injection enhances the market competitiveness of Jiangxi Gannan Haixin and contributes to the accumulation of experience for future drug development [6]. - The current operational performance of the company is not expected to be significantly impacted by this approval [6].

Group 1 - Zhuolang Intelligent's subsidiary plans to increase capital by 900 million yuan to its wholly-owned subsidiary in Xinjiang [1] - Zhenhua Heavy Industry signed a contract worth 1.149 billion yuan with Guangzhou Salvage Bureau for a deep-water crane ship construction project [2] - Ugreen Technology intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its global strategy [3] Group 2 - Guangsheng Nonferrous Metals will change its stock name to Zhongxi Rare Metals starting December 31, 2025 [4] - China Electric Research proposed a cash dividend of 2.5 yuan per 10 shares for the first three quarters of 2025 [5] - Chaoyan Co. is establishing a fund with professional investment institutions, aiming to raise 1 billion yuan [6] Group 3 - Silk Road Vision's subsidiary plans to sell 8.5% of Ruijun Technology for 52.7 million yuan [7] - Longgao Co.'s actual controller is transferring 4.37% of the investment development group's equity for 398 million yuan [8] - Weiteou signed a strategic cooperation agreement with Huaruixin Energy to develop new materials and applications [9][10] Group 4 - Annuoqi decided to terminate the investment in a 50,000-ton dye intermediate project due to market changes, with a total investment of 421 million yuan [12] - Akoli's subsidiary has entered trial production for a project with an annual capacity of 20,000 tons of polyether amine [13] - Ningbo Construction's subsidiary signed a construction contract worth 451 million yuan for a comprehensive utility tunnel project [14] Group 5 - Zhejiang Rongtai and Weichuang Electric plan to establish a joint venture in Thailand for R&D and production of mechatronic components [15] - Jiuzhoutong's subsidiary received a drug registration certificate for isopropazine injection [16] - Huaqin Technology's subsidiary signed a daily operation contract worth 392 million yuan [17] Group 6 - ST Meichen completed the sale of 100% equity in Hainan Meichen Ecological Development Co., Ltd. [18] - Pulite's LCP film products have begun mass production for a leading customer in the consumer electronics industry [19][20] - Nanjing Public Utility's major shareholder transferred 7.61% of the company's shares for 300 million yuan [21] Group 7 - Solar Energy terminated the investment in a 150 MW distributed photovoltaic project due to increased investment risks [22] - Yuntian Lifa won a 122 million yuan project for AI development in Longgang [23] - Changchun High-tech's subsidiary received acceptance for a clinical trial application for GenSci141 ointment [24] Group 8 - Changfei Optical Fiber's major shareholder completed a share reduction plan, selling 1.1 million shares for approximately 104.5 million yuan [25] - Sandam Membrane plans to apply for a comprehensive credit limit of up to 100 million yuan for 2026 [26] - Aisecurity received a government subsidy of 3.4611 million yuan [27] Group 9 - Stone Technology's H-share issuance has received approval from the China Securities Regulatory Commission [28] - Hongxing Development's subsidiary plans to suspend production to comply with national hazardous chemical relocation policies [29] - Guodian Nanzi's vice president and chief engineer resigned [30] Group 10 - Jianghe Group's subsidiary won a bid for a city renovation project in Haikou worth approximately 112 million yuan [31] - Gaotie Electric's subsidiary won a bid for a railway project worth 59.0317 million yuan [32] - Huicheng Co. plans to introduce a new partner to its major shareholder [33] Group 11 - Pumen Technology's folic acid testing kit received a medical device registration certificate [34] - Hai Xin Co.'s vitamin B6 injection passed the consistency evaluation for generic drugs [35] - Taiji Group's shareholder plans to merge with its subsidiary [36] Group 12 - Shengyi Electronics adjusted the maximum repurchase price to no more than 144.36 yuan per share [37]

Core Viewpoint - The company, Haixin Co., Ltd. (600851.SH), announced that its subsidiary, Jiangxi Gannan Haixin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the supplement application of the chemical drug "Vitamin B6 Injection," which has passed the consistency evaluation of generic drug quality and efficacy [1] Group 1 - The approved drug, Vitamin B6 Injection, is primarily indicated for the prevention and treatment of Vitamin B6 deficiency and for treating isoniazid poisoning [1] - Additional indications include use during pregnancy, radiation sickness, and vomiting caused by anticancer drugs, as well as seborrheic dermatitis [1] - The drug is also indicated for total parenteral nutrition and for nutritional deficiencies due to inadequate intake, as well as for progressive weight loss [1] Group 2 - Increased demand for Vitamin B6 may arise in conditions such as pregnancy and lactation, hyperthyroidism, burns, chronic infections, fever, congenital metabolic disorders, congestive heart failure, long-term dialysis, and malabsorption syndromes associated with liver and biliary diseases [1] - The drug is also indicated for gastrointestinal diseases, including celiac disease, tropical enteritis, localized enteritis, and persistent diarrhea, as well as post-gastrectomy [1] - It is specifically indicated for newborns with hereditary Vitamin B6 dependency syndrome [1]

证券代码：600851/900917 证券简称：海欣股份/海欣B股 公告编号：2025-035 上海海欣集团股份有限公司 关于子公司药品通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、药品基本情况 药品名称：维生素 B6注射液 剂型：注射剂 规格：1ml：0.1g 注册分类：化学药品 药品批准文号：国药准字 H20258295 通知书编号：2025B06189 上市许可持有人：江西赣南海欣药业股份有限公司 审批结论：根据《中华人民共和国药品管理法》《国务院关于改革药品医疗器械 审评审批制度的意见》（国发〔2015〕44 号）《关于仿制药质量和疗效一致性评价工 作有关事项的公告》（2017 年第 100 号）和《国家药监局关于开展化学药品注射剂仿 制药质量和疗效一致性评价工作的公告》（2020 年第 62 号）的规定，经审查，批准 本品增加 1m1:0.1g 规格，核发药品批准文号，本品通过仿制药质量和疗效一致性评价。 生产工艺、质量标准与说明书照所附执行，标签相关内容应与说明书保持一致。有 ...